
ANGIOPLASTY VS BYPASS: FEMOROPOPLITEAL OCCLUSIVE DISEASE

WINNIPEG VASCULAR & ENDOVASCULAR SYMPOSIUM 2026

KELSEY AMBROSE

PGY4 VASCULAR SURGERY
WESTERN UNIVERSITY

PRESENTER DISCLOSURE

- I have no current relationships with commercial entities.



CHRONIC CLIMB THREATENING ISCHEMIA

CLTI is a clinical syndrome defined by the presence of peripheral artery disease AND:

- Rest pain
- Gangrene
- Lower limb ulceration >2 weeks duration

Within 1 year of presentation:

25% progress to major limb amputation

25% die of cardiovascular complications

OPEN SURGERY VS. ENDOVASCULAR


-
- Technical success
 - Morbidity and mortality
 - Patency, reintervention rates
 - Limb preservation

CASE

- 65-year-old woman
- T2DM, HTN, DLD
- 50 pack/year smoker

- Left leg rest pain, no tissue loss
- Employed in a warehouse

- Palpable femoral pulse
- ABI 0.4



Left leg GSV:

- 4 mm thigh
- 3 mm knee
- 3 mm ankle

What procedure would you offer?


- A. Endovascular recanalization
- B. Open bypass with GSV
- C. Open bypass with alternative vein
- D. Open bypass with prosthetic

2000-

TRANS-ATLANTIC INTER-SOCIETY CONSENSUS DOCUMENT


Type A lesions

- Single stenosis ≤ 10 cm in length
- Single occlusion ≤ 5 cm in length



Type B lesions:

- Multiple lesions (stenoses or occlusions), each ≤ 5 cm
- Single stenosis or occlusion ≤ 15 cm not involving the infrageniculate popliteal artery
- Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass
- Heavily calcified occlusion ≤ 5 cm in length
- Single popliteal stenosis




Type C lesions

- Multiple stenoses or occlusions totaling > 15 cm with or without heavy calcification
- Recurrent stenoses or occlusions that need treatment after two endovascular interventions



Type D lesions

- Chronic total occlusions of CFA or SFA (> 20 cm, involving the popliteal artery)
- Chronic total occlusion of popliteal artery and proximal trifurcation vessels




2000-

TRANS-ATLANTIC INTER-SOCIETY CONSENSUS DOCUMENT

Type A lesions


- Single stenosis ≤ 10 cm in length
- Single occlusion ≤ 5 cm in length



ENDO

Type B lesions:

- Multiple lesions (stenoses or occlusions), each ≤ 5 cm
- Single stenosis or occlusion ≤ 15 cm not involving the infrageniculate popliteal artery
- Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass
- Heavily calcified occlusion ≤ 5 cm in length
- Single popliteal stenosis



Type C lesions


- Multiple stenoses or occlusions totaling >15 cm with or without heavy calcification
- Recurrent stenoses or occlusions that need treatment after two endovascular interventions



OPEN

Type D lesions

- Chronic total occlusions of CFA or SFA (>20 cm, involving the popliteal artery)
- Chronic total occlusion of popliteal artery and proximal trifurcation vessels



2019- GLOBAL VASCULAR GUIDELINES

■ Evidence-based revascularization “PLAN”



Patient Risk

- Comorbidities



Limb Severity

- WiFi Classification



Anatomic Complexity

- GLASS

THE GLOBAL LIMB ANATOMIC STAGING SYSTEM (GLASS)

Femoro-Popliteal (FP) Grading

0	Mild or no significant (<50%) disease
1	Total length SFA disease <1/3 (<10 cm); may include single focal CTO (<5 cm) as long as not flush occlusion; popliteal artery with mild or no significant disease
2	Total length SFA disease 1/3-2/3 (10-20 cm); may include CTO totaling <1/3 (10 cm) but not flush occlusion; focal popliteal artery stenosis <2 cm, not involving trifurcation
3	Total length SFA disease >2/3 (>20 cm) length; may include any flush occlusion <20 cm or non-flush CTO 10-20 cm long; short popliteal stenosis 2-5 cm, not involving trifurcation
4	Total length SFA occlusion >20 cm; popliteal disease >5 cm or extending into trifurcation; any popliteal CTO

Infra-Popliteal (IP) Grading

0	Mild or no significant (<50%) disease
1	Focal stenosis <3 cm not including TP trunk
2	Total length of target artery disease <1/3 (<10 cm); single focal CTO (<3 cm not including TP trunk or target artery origin)
3	Total length of target artery disease 1/3-2/3 (10-20 cm); CTO 3-10 cm (may include target artery origin, but not TP trunk)
4	Total length of target artery disease >2/3 length; CTO >1/3 (>10 cm) of length (may include target artery origin); any CTO of TP trunk

THE GLOBAL LIMB ANATOMIC STAGING SYSTEM (GLASS)

GLASS stages based on FP and IP grade.

		Infringuinal GLASS Stage				
FP Grade	4	III	III	III	III	III
	3	II	II	II	III	III
	2	I	II	II	II	III
	1	I	I	II	II	III
	0	NA	I	I	II	III
		0	1	2	3	4
		IP Grade				

- **Stage 1: Average Complexity**
 - Technical failure <10%
 - I-year LBP >70%
- **Stage 2: Intermediate Complexity**
 - Technical failure <20%
 - I-year LBP 50-70%
- **Stage 3: High Complexity**
 - Technical failure >20%
 - I-year LBP <50%

BYPASS VERSUS ANGIOPLASTY IN SEVERE ISCHEMIA OF THE LEG

2005 BASIL

- Bypass (75% vein) (228) vs POBA (224)
- Primary Outcome: Amputation free survival

	Bypass	POBA
Technical Success	97%	80%
Reintervention	18% at 1 year	26% at 1 year
Morbidity	57% (wound complications)	41%
Mortality	No difference at 30 days * Beyond 2 years, greater overall survival	No difference at 30 days
Major Amputation	*Beyond 2 years, greater amputation free survival	

SURGERY OR ENDOVASCULAR THERAPY FOR CHRONIC LIMB-THREATENING ISCHEMIA

2022 BEST-CLI

- **Cohort I:** Single segment GSV bypass (709) vs best endovascular treatment (711)
 - Primary Outcome: Composite of death or MALE

	GSV Bypass	Endovascular
Reintervention	14%	26% **66 of 108 cases of early failure were treated with bypass within 30d
Morbidity	No difference of MACE within 30d	
Mortality	No difference in perioperative mortality	
Major Amputation	10.4%	14.9%

VEIN BYPASS FIRST VERSUS BEST ENDOVASCULAR TREATMENT FIRST REVASCULARISATION STRATEGY FOR PATIENTS WITH CLTI

2023
BASIL-2

- Infrapopliteal vein bypass (172) vs best endovascular treatment (173)
 - Primary Outcome: Amputation free survival

	Vein Bypass	Endovascular
Reintervention	5%	19%
Morbidity	No significant difference (42-46%)	
Mortality	53% at 2 years 6% at 30 days Cardiovascular and respiratory events were the dominant cause of death within 30 days	45% at 2 years 3% at 30 days
Limb Preservation	No significant difference (18-20%)	

TAKEAWAYS

2005 BASIL

- Patients >2 year life expectancy should receive **open surgery first approach**

2022 BEST CLI

- Patients with ssGSV should receive **open surgery first approach**

2023 BASIL-2

- Patients have **higher morality after open surgery**, but similar limb-based outcomes

Endovascular intervention had universally higher re-intervention rates


Patients with CLTI, suitable single segment GSV and reasonable operative risk profile should receive an open surgery first approach

CASE

- 65-year-old woman
- T2DM, HTN, DLD
- 50 pack/year smoker

- Left leg rest pain, no tissue loss
- Employed in a warehouse

- Palpable femoral pulse
- ABI 0.4



Bilateral GSV:

- stripped

What procedure would you offer?

- A. Endovascular recanalization
- ~~B. Open bypass with GSV~~
- C. Open bypass with alternative vein
- D. Open bypass with prosthetic

ALTERNATIVE BYPASS CONDUIT VS ENDOVASCULAR

2022 BEST-CLI

- **Cohort 2:** Alternative conduit bypass (194) vs best endovascular (199)
 - 48 alternative vein, 119 prosthetic
 - 50% Fem-pop, 41% Fem-tib, and 9% Pop-tib targets
 - Primary Outcome: Composite of death or MALE

	Alternative Bypass	Endovascular
Technical Success	100%	80% 26 of 37 patients underwent bypass within 30d
Morbidity	No difference of MACE within 30d	
Reintervention (1.6 years)	**14%	26%
Mortality	No difference in perioperative mortality	
Limb Preservation	No significant difference (14-15%)	

*** Expected 2-year primary patency for prosthetic (50-60%) and alternative vein (50-70%)*

“BURNING BRIDGES”: DOES ENDO FIRST IMPEDE FUTURE BYPASS?

European Journal of
Vascular & Endovascular Surgery

Editor's Choice – Bypass After Failed Endovascular Intervention Is Associated with an Increased Risk of Above Ankle Amputation Among Patients with Chronic Limb Threatening Ischaemia in a Randomised Trial Population

Alik Farber ^{a,*}, Matthew T. Menard ^b, Michael S. Conte ^c, Kenneth Rosenfield ^d, Caitlin W. Hicks ^e, Gheorge Doros ^a, Michael B. Strong ^b, Kim Houlind ^f, Philippe Kolh ^g, Jeffrey J. Siracuse ^a

- Secondary analysis of BEST CLI data
- Cohort 1: 665 primary bypass and 158 secondary bypass | Cohort 2: 192 primary bypass and 45 secondary bypass
- Time to SB after ENDO occurred at a median of 28 days in all patients and at a median of 210 days in those who had a successful initial ENDO procedure.
- Secondary bypass was associated with **increased above ankle amputation in cohort 1 (13.5% vs. 7.4%)**
- **Not statistically significant in cohort 2 (15.9% vs. 10.9%)**

“BURNING BRIDGES”: DOES ENDO FIRST IMPEDE FUTURE BYPASS?

European Journal of
Vascular & Endovascular Surgery

Editor's Choice — Infrainguinal Bypass Following Failed Endovascular Intervention Compared With Primary Bypass: A Systematic Review and Meta-Analysis[☆]

Saiiid Hossain^a, Dominic Leblanc^a, Alik Farber^b, Adam H. Power^a,
Guy DeRose^a, Audra Duncan^a, Luc Dubois^{a,c,*}

- 15 studies involving 11,886 patients
- Primary bypass vs bypass after failed endovascular intervention
- No difference in 30 day mortality or 30 day amputation rates
- **One year amputation free survival was higher in primary bypass**
- **Worse one-year primary patency in bypass after failed endovascular intervention**
 - Change in distal target after failed endovascular

CASE

- 80-year-old woman
- T2DM, HTN, DLD, CKD
- 70 pack/year smoker

- Great toe dry gangrene
 - **WiFi stage 4 (2,3,0)**
- From home, caregiver for spouse

- Palpable femoral pulse
- ABI 0.3



Bilateral GSV:


- stripped

What procedure would you offer?

- A. Endovascular recanalization
- B. Open bypass with alternative vein
- C. Open bypass with prosthetic
- D. Primary amputation

CONCLUSIONS

- **Revascularization is nuanced.** Not “one size fits all”
 - Dependent on anatomy, conduit availability, patient factors
- If a patient has a suitable ssGSV, and a reasonable life expectancy/risk profile, **open bypass should be offered first**
- There is **equivalence of endo vs alternative bypass**
 - Recognize that many patients will require repeat interventions, **plan to “fail forward”**
 - In single vessel runoff, attempt alternative bypass before endovascular intervention



REFERENCES

- Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, Hamza TH, Assmann SF, Creager MA, Cziraky MJ, Dake MD. Surgery or endovascular therapy for chronic limb-threatening ischemia. *New England Journal of Medicine*. 2022 Dec 22;387(25):2305-16.
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Tasc II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). *Journal of vascular surgery*. 2007 Jan 1;45(1):S5-67.
- Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH, Aboyans V. Global vascular guidelines on the management of chronic limb-threatening ischemia. *European Journal of Vascular and Endovascular Surgery*. 2019 Jul 1;58(1):S1-09.
- El Khoury R, Wu B, Edwards CT, Lancaster EM, Hiramoto JS, Vartanian SM, Schneider PA, Conte MS. The Global Limb Anatomic Staging System is associated with outcomes of infrainguinal revascularization in chronic limb threatening ischemia. *Journal of Vascular Surgery*. 2021 Jun 1;73(6):2009-20.
- Bradbury AW, Ruckley CV, Fowkes FG, Forbes JF, Gillespie I, Adam DJ. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet*. 2005 Dec 3;366(9501):1925-34.
- Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, Chetter I, Diamantopoulos A, Ganeshan A, Hall J, Hobbs S. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. *The Lancet*. 2023 May 27;401(10390):1798-809.
- Gombert A. Bypass after Failed Endovascular Intervention is Associated with an Increased Risk of Above Ankle Amputation: Do It Right, Do It Once?. *European Journal of Vascular and Endovascular Surgery*. 2025 Jul 1;70(1):114.
- Hossain S, Leblanc D, Farber A, Power AH, DeRose G, Duncan A, Dubois L. Infrainguinal Bypass Following Failed Endovascular Intervention Compared With Primary Bypass: A Systematic Review and Meta-Analysis. *Journal of Vascular Surgery*. 2019 May 1;69(5):1648-9.
- Roy T, Forbes T, Wright G, Dueck A. Burning bridges: mechanisms and implications of endovascular failure in the treatment of peripheral artery disease. *Journal of Endovascular Therapy*. 2015 Dec;22(6):874-80.